Comparative effects of sirolimus and cyclosporin on conduit arteries endothelial function in kidney recipients

Transplant International

Volumn 23, Issue 11, 2010, Pages 1135-1143

  Joannides, Robinson ^a   Etienne, Isabelle ^a   Iacob, Michele ^a   De Ligny, Bruno Hurault ^b   Barbier, Stephane ^a   Bellien, Jeremy ^a   Lebranchu, Yvon ^c   Thuillez, Christian ^a   Godin, Michel ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE TOURS   (France)

Author keywords

artery; cyclosporin; endothelium; sirolimus; transplantation

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY;

ADULT; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HYPEREMIA; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

ADULT; ARTERIES; BLOOD PRESSURE; CYCLOSPORINE; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISCHEMIA; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS;

EID: 77957572222     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01122.x     Document Type: Article

References (55)

1. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006 82 : 603.
2. Gill JS. Cardiovascular disease in transplant recipients: current and future treatment strategies. Clin J Am Soc Nephrol 2008 3 (Suppl. 2 S29.
3. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007 115 : 1285.
4. Passauer J, Büssemaker E, Lassig G, Gross P. Kidney transplantation improves endothelium-dependent vasodilation in patients with end stage renal disease. Transplantation 2003 75 : 1907.
5. Hausberg M, Kisters K, Kosch M, Rahn KH, Barenbrock M. Flow-mediated vasodilation and distensibility of the brachial artery in renal allograft recipients. Kidney Int 1999 55 : 1104.
6. Kosch M, Hausberg M, Suwelack B. Studies on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Transplantation 2003 76 : 1516.
7. Ovuworie CA, Fox ER, Chow CM, et al. Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. Transplantation 2001 72 : 1385.
8. Morris ST, McMurray JJ, Rodger RS, Farmer R, Jardine AG. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int 2000 57 : 1100.
9. Woywodt A, Schroeder M, Mengel M, et al. Circulating endothelial cells are a novel marker of cyclosporine-induced endothelial damage. Hypertension 2003 41 : 720.
10. Mercanoglu F, Turkmen A, Kocaman O, et al. Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels. Transplant Proc 2004 36 : 1357.
11. Gallego MJ, García Villalón AL, López Farre AJ, et al. Mechanisms of endothelial cell toxicity of cyclosporine A. Role of nitric oxide, cGMP, and Ca2+. Circ Res 1994 74 : 477.
12. Harris MB, Ju H, Venema VJ, et al. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem 2001 276 : 16587.
13. Lungu AO, Jin ZG, Yamawaki H, Tanimoto T, Wong C, Berk BC. Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae. J Biol Chem 2004 279 : 48794.
14. Diederich D, Skopec J, Diederich A, Dai FX. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension 1994 23 : 957.
15. Calò LA, Davis PA, Giacon B, et al. Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol 2002 40 : 625.
16. Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 1991 88 : 310.
17. Ramzy D, Rao V, Tumiati LC, et al. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine. Circulation 2006 114 (Suppl. I I214.
18. Saurina A, Campistol JM, Lario S, Oppenheimer F, Diekmann F. Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration. Transplant Proc 2007 39 : 2138.
19. Kaye D, Thompson J, Jennings G, Esler M. Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. Circulation 1993 88 : 1101.
20. Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001 16 (Suppl. 1 121.
21. Ekberg H, Tedesco-Silva H, Demirbas A, et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 357 : 2562.
22. Oflaz H, Turkmen A, Kazancioglu R, et al. The effect of calcineurin inhibitors on endothelial function in renal transplant recipients. Clin Transplant 2003 17 : 212.
23. Yilmaz MI, Saglam M, Caglar K, et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005 80 : 1660.
24. Wissing KM, Unger P, Ghisdal L, et al. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. Transplantation 2006 82 : 771.
25. Yilmaz MI, Saglam M, Carrero JJ, et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatinNAMPT. A novel marker of endothelial damage? Clin Transplant 2009 23 : 241.
26. Cook LG, Chiasson VL, Long C, Wu GY, Mitchell BM. Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect. Kidney Int 2009 75 : 719.
27. Morath C, Arns W, Schwenger V, et al. Sirolimus in renal transplantation. Nephrol Dial Transplant 2007 22 (Suppl. 8 S61.
28. Milliard S, Silva A, Blaise G, et al. Rapamycin's effect on vasomotion in the rat. Transplant Proc 1998 30 : 1036.
29. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007 116 : 2726.
30. Steffel J, Latini RA, Akhmedov A, et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 2005 112 : 2002.
31. Jabs A, Göbel S, Wenzel P, et al. Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. J Am Coll Cardiol 2008 51 : 2130.
32. Barilli A, Visigalli R, Sala R, et al. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res 2008 78 : 563.
33. Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001 72 : 777.
34. Büchler M, Caillard S, Barbier S, et al. SPIESSER Group. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007 7 : 2522.
35. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009 9 : 1115.
36. Joannides R, Bakkali EH, Le Roy F, et al. Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol Dial Transplant 1997 12 : 2623.
37. Joannides R, Bellien J, Thurlure C, Iacob M, Abeel M, Thuillez C. Fixed combination of perindopril and indapamide at low dose improves endothelial function in essential hypertensive patients after acute administration. Am J Hypertens 2008 21 : 679.
38. Pyke KE, Tschakovsky ME. Peak vs. total reactive hyperaemia: which determines the magnitude of flow-mediated dilation? J Appl Physiol 2007 102 : 1510.
39. Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008 8 : 1384.
40. Limbourg FP, Huang Z, Plumier JC, et al. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest 2002 110 : 1729.
41. Bauersachs J, Christ M, Ertl G, et al. Cytochrome P450 2C expression and EDHF-mediated relaxation in porcine coronary arteries is increased by cortisol. Cardiovasc Res 2002 54 : 669.
42. Dover AR, Hadoke PW, Walker BR, Newby DE. Acute effects of glucocorticoids on endothelial fibrinolytic and vasodilator function in humans. J Cardiovasc Pharmacol 2007 50 : 321.
43. Mangos GJ, Walker BR, Kelly JJ, Lawson JA, Webb DJ, Whitworth JA. Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens 2000 13 : 1155.
44. Iuchi T, Akaike M, Mitsui T, et al. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 2003 92 : 81.
45. van den Dorpel MA, van den Meiracker AH, Lameris TW, Weimar W, Man in't Veld AJ. Forearm vasorelaxation in hypertensive renal transplant patients: the impact of withdrawal of cyclosporine. J Hypertens 1998 16 : 331.
46. Joannides R, Richard V, Thuillez C. Pulsatile stress, arterial stiffness, endothelial function. In : Safar ME, O'Rourke ME, eds. Handbook of Hypertension, Arterial Stiffness in Hypertension.
47. Bellien J, Joannides R, Iacob M, Arnaud P, Thuillez C. Calcium-activated potassium channels and NO regulate human peripheral conduit artery mechanics. Hypertension 2005 46 : 210.
48. Woywodt A, Schroeder M, Gwinner W, et al. Elevated numbers of circulating endothelial cells in renal transplant recipients. Transplantation 2003 76 : 1.
49. Caillard S, Leray C, Kunz K, et al. Effects of cerivastatin on lipid profiles, lipid peroxidation and platelet and endothelial activation in renal transplant recipients. Transplant Proc 2000 32 : 2787.
50. Raichlin E, Prasad A, Kremers WK, et al. Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable cardiac transplant recipients. Eur Heart J 2009 30 : 1356.
51. Albillos A, Cacho G, Barrios C, et al. Selective impairment of endothelium-mediated vasodilation in liver transplant recipients with cyclosporin A-induced hypertension. Hepatology 1998 27 : 332.
52. Bracht C, Yan XW, LaRocca HP, Sütsch G, Kiowski W. Cyclosporine A and control of vascular tone in the human forearm: influence of post-transplant hypertension. J Hypertens 1999 17 : 357.
53. Haug C, Schmid-Kotsas A, Linder T, et al. The immunosuppressive drug mycophenolic acid reduces endothelin-1 synthesis in endothelial cells and renal epithelial cells. Clin Sci (Lond) 2002 103 (Suppl. 48 S76.
54. Krötz F, Keller M, Derflinger S, et al. Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a Rac1-dependent mechanism. Hypertension 2007 49 : 201.
55. Picard N, Prémaud A, Rousseau A, Le Meur Y, Marquet P. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol 2006 62 : 477.